GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy

GSK (GSK.L) will pay about $1 billion for exclusive rights to further develop and commercialize Johnson & Johnson's (JNJ.N) hepatitis B therapy, the British drugmaker said on Tuesday.

JNJ-3989 was initially developed by Arrowhead Pharmaceuticals (ARWR.O) and licensed to Johnson & Johnson-owned Janssen in 2018.